title: Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase.
abstract: We developed a novel approach to assess tumor vascularity using recombinant Gaussia luciferase (rGluc) protein and bioluminescence imaging. Upon intravenous injection of rGluc followed by its substrate coelenterazine, non-invasive visualization of tumor vascularity by bioluminescence imaging was possible. We applied this method for longitudinal monitoring of tumor vascularity in response to the anti-angiogenic drug tivozanib. This simple and sensitive method could be extended to image blood vessels/vasculature in many different fields.
authors.affiliation: Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.|Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Rami S
authors.initials: RS
authors.lastname: Kantar
authors.affiliation: Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.|Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Ghazal
authors.initials: G
authors.lastname: Lashgari
authors.affiliation: Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.|Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Elie I
authors.initials: EI
authors.lastname: Tabet
authors.affiliation: Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.|Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Grant K
authors.initials: GK
authors.lastname: Lewandrowski
authors.affiliation: Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.|Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Litia A
authors.initials: LA
authors.lastname: Carvalho
authors.affiliation: Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.|Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Bakhos A
authors.initials: BA
authors.lastname: Tannous
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D045744:Cell Line, Tumor; D033342:Copepoda / Q000201:enzymology; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008156:Luciferases / Q000378:metabolism*; D049408:Luminescent Agents / Q000008:administration & dosage*; D008163:Luminescent Measurements; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D010671:Phenylurea Compounds / Q000008:administration & dosage*; D011719:Pyrazines / Q000008:administration & dosage*; D011804:Quinolines / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D007093:Imidazoles; D049408:Luminescent Agents; D010671:Phenylurea Compounds; D011719:Pyrazines; D011804:Quinolines; D011994:Recombinant Proteins; C553176:tivozanib; C017144:coelenterazine; D008156:Luciferases